- Home
- NRDS vs NUVB Comparison
NRDS vs NUVB Comparison
Compare NRDS & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRDS
- NUVB
- Stock Information
- Founded
- NRDS 2009
- NUVB 2018
- Country
- NRDS United States
- NUVB United States
- Employees
- NRDS N/A
- NUVB N/A
- Industry
- NRDS EDP Services
- NUVB Biotechnology: Pharmaceutical Preparations
- Sector
- NRDS Technology
- NUVB Health Care
- Exchange
- NRDS Nasdaq
- NUVB Nasdaq
- Market Cap
- NRDS 953.9M
- NUVB 850.3M
- IPO Year
- NRDS 2021
- NUVB N/A
- Fundamental
- Price
- NRDS $13.97
- NUVB $2.70
- Analyst Decision
- NRDS Buy
- NUVB Strong Buy
- Analyst Count
- NRDS 6
- NUVB 6
- Target Price
- NRDS $17.00
- NUVB $6.33
- AVG Volume (30 Days)
- NRDS 1.0M
- NUVB 2.3M
- Earning Date
- NRDS 10-29-2024
- NUVB 11-06-2024
- Dividend Yield
- NRDS N/A
- NUVB N/A
- EPS Growth
- NRDS N/A
- NUVB N/A
- EPS
- NRDS N/A
- NUVB N/A
- Revenue
- NRDS $637,500,000.00
- NUVB $2,162,000.00
- Revenue This Year
- NRDS $14.44
- NUVB N/A
- Revenue Next Year
- NRDS $12.90
- NUVB N/A
- P/E Ratio
- NRDS N/A
- NUVB N/A
- Revenue Growth
- NRDS 4.90
- NUVB N/A
- 52 Week Low
- NRDS $10.10
- NUVB $1.22
- 52 Week High
- NRDS $17.30
- NUVB $4.16
- Technical
- Relative Strength Index (RSI)
- NRDS 51.68
- NUVB 54.67
- Support Level
- NRDS $12.89
- NUVB $2.44
- Resistance Level
- NRDS $15.65
- NUVB $3.07
- Average True Range (ATR)
- NRDS 0.74
- NUVB 0.18
- MACD
- NRDS -0.24
- NUVB -0.00
- Stochastic Oscillator
- NRDS 30.35
- NUVB 57.78
About NRDS NerdWallet Inc.
Nerdwallet Inc is a company that provides onsumer-driven advice about personal finance through its platform by connecting individuals and small and mid-sized businesses (SMBs) with providers of financial products. They get revenue from fees paid by its financial services partners in the form of either revenue per action, revenue per click, revenue per lead and revenue per funded loan arrangements.
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).